arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Anebulo Pharmaceuticals, Inc.

ANEB

— Price unavailable

23 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Anebulo Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -26.1% ↘

FCF / Share $-0.03 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

23-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-2.16M

↑ +1.9% —

FCF / Share Free cash flow per share

$-0.03

↓ -3.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
EPS Growth YoY (%)	44.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	37.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	33.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	18.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	20.0% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	50.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	45.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	26.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	9.1% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	-37.5% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-200.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-57.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	1.9% Caution ↑ Caution Improving Year-over-year change in net income	1.9% Caution ↑ Caution Improving Year-over-year change in net income	-58.9% Weak ↓ Weak Declining Year-over-year change in net income	11.3% Fair ↓ Fair Declining Year-over-year change in net income	11.3% Fair ↓ Fair Declining Year-over-year change in net income	11.3% Fair ↓ Fair Declining Year-over-year change in net income	45.9% Excellent ↑ Excellent Improving Year-over-year change in net income	5.0% Fair ↑ Fair Improving Year-over-year change in net income	5.0% Fair ↑ Fair Improving Year-over-year change in net income	5.0% Fair ↑ Fair Improving Year-over-year change in net income	-7.4% Weak ↑ Weak Improving Year-over-year change in net income	-68.1% Weak ↓ Weak Declining Year-over-year change in net income	-68.1% Weak ↓ Weak Declining Year-over-year change in net income	-68.1% Weak ↑ Weak Improving Year-over-year change in net income	92.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-179.5% Weak ↑ Weak Improving Year-over-year change in net income	-505.9% Weak Weak Year-over-year change in net income	-505.9% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	—	52.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	38.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-22.5% Weak Weak Year-over-year change in free cash flow	—	—	—	-160.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
FCF / Net Income (x)	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.52x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.14x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.50x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.12x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.60x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
Return on Invested Capital (%)	-26.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-11.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-100.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.8% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-26.4% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-33.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	35.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-27.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-97.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.8% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-36.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-14.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	-11.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-27.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-281%)	-22.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-248%)	-18.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-223%)	-16.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	-14.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-198%)	-115.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-873%)	-35.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-336%)	-49.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-432%)	-38.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-355%)	-29.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-299%)	-23.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-257%)	-20.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	-16.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-212%)	-13.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-191%)	-15.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-203%)	-9.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-160%)	-8.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-155%)	-7.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-152%)	-136.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1006%)	5.9% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-61%)	35.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+138%)	62.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+316%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
Interest Coverage (x)	-154.11x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-132.96x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-7.77x Weak Weak Operating income divided by interest expense Optimal: > 5x	-18.92x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-12.36x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-27.88x Weak Weak Operating income divided by interest expense Optimal: > 5x	-86.70x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-9.04M	$-10.35M	$-11.63M	$-13.28M	$-15.00M	$-1.40M	$-3.09M	$-5.15M	$-6.64M	$-8.52M	$-11.25M	—	—	—	—	—	—	—	—	$-3.31M	—	—	$-3.02M

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
Basic EPS, GAAP (USD)	$-0.05	$-0.05	$-0.05	$-0.04	$-0.09	$-0.08	$-0.05	$-0.06	$-0.11	$-0.10	$-0.10	$-0.11	$-0.15	$-0.11	$0.48	$-0.08	$-0.05	$-0.07	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.03	$-0.03	—	$-0.04	—	$-0.07	—	—	—	$-0.11	—	—	—	$-0.09	—	$-0.06	$-0.05	$-0.03	—	—	—	—	—
Book Value per Share (USD)	$0.19	$0.24	$0.28	$0.33	$0.36	$0.07	$0.15	$0.19	$0.25	$0.33	$0.41	$0.50	$0.61	$0.75	$0.65	$0.74	$0.81	$0.85	$0.92	$-0.73	—	—	$-0.01
Tangible Book Value per Share (USD)	$0.19	$0.24	$0.28	$0.33	$0.36	$0.07	$0.15	$0.19	$0.25	$0.33	$0.41	$0.50	$0.61	$0.75	$0.65	$0.74	$0.81	$0.85	$0.92	$-0.73	—	—	$-0.01
Basic Weighted Avg Shares (shares)	41.08M	41.08M	—	41.08M	27.42M	25.93M	—	25.93M	25.79M	25.63M	—	25.63M	25.63M	23.42M	—	23.34M	23.34M	23.34M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
Working Capital (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$3.61M	—	—	$2.80M
Total Equity (USD)	$7.94M	$9.74M	$11.66M	$13.46M	$14.96M	$1.90M	$3.81M	$4.99M	$6.49M	$8.33M	$10.60M	$12.94M	$15.52M	$19.12M	$15.07M	$17.16M	$18.91M	$19.89M	$21.41M	$-9.44M	$-719.02K	$-411.11K	$-171.14K

📋 What is driving earnings? 2 metrics

Metric	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q3 FY2023 Mar 31, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2022 10-Q ↗	Q1 FY2023 Sep 30, 2022 10-Q ↗	Q4 FY2022 Jun 30, 2022 10-K ↗	Q3 FY2022 Mar 31, 2022 10-Q ↗	Q2 FY2022 Dec 31, 2021 10-Q ↗	Q1 FY2022 Sep 30, 2021 10-Q ↗	Q4 FY2021 Jun 30, 2021 10-K ↗	Q3 FY2021 Mar 31, 2021 10-Q ↗	Q2 FY2021 Dec 31, 2020 10-Q ↗	Q1 FY2021 Sep 30, 2020 10-Q ↗	Q4 FY2020 Jun 30, 2020 10-Q ↗
Net Income, GAAP (USD)	$-2.16M	$-2.16M	$-2.14M	$-2.20M	$-2.20M	$-2.20M	$-1.35M	$-2.48M	$-2.48M	$-2.48M	$-2.50M	$-2.61M	$-2.61M	$-2.61M	$-2.32M	$-1.55M	$-1.55M	$-1.55M	$-29.11M	$-555.83K	$-256.38K	$-256.38K	—
Operating Cash Flow (USD)	$-1.31M	$-1.27M	$-1.65M	$-1.60M	—	$-1.69M	$-2.05M	—	—	$-2.73M	$-2.85M	—	—	$-2.03M	$-2.00M	$-1.46M	$-1.20M	$-777.90K	$-3.50M	—	$-410.02K	$-134.96K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 23 quarters

Anebulo Pharmaceuticals, Inc.

Analytical Summary

23-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ANEB with peers